Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CodeBreaK 201 first-line sotorasib in KRAS G12C-mutant stage IV NSCLC
NL-OMON51994Phase 2Withdrawn
- Sponsor
- Amgen
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sotorasib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Amgen. Primary endpoint: Objective response rate. Planned start Aug 2021; status: withdrawn.
02
Drugs
sotorasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON51994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51994.